Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTR1E | P28566 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611249 | 1.00 | MEN1 (0.32) | MEN1MAPTKMT2AHTTLMNA | |
| SCHEMBL6603938 | 0.84 | KDM4E (0.34) | MEN1KMT2AALDH1A1FFAR4 | |
| SCHEMBL6603949 | 0.84 | KDM4E (0.34) | MEN1KMT2AALDH1A1FFAR4 | |
| SCHEMBL6606465 | 0.81 | — | — | |
| SCHEMBL6606456 | 0.81 | — | — | |
| SCHEMBL6760982 | 0.79 | AKR1B1 (0.34) | — | |
| SCHEMBL5399566 | 0.76 | MEN1 (0.36) | MEN1MAPTKMT2AHTTLMNA | |
| SCHEMBL5399558 | 0.76 | MEN1 (0.36) | MEN1MAPTKMT2AHTTLMNA | |
| SCHEMBL6608265 | 0.75 | PDE4A (0.33) | MEN1MAPTKMT2AHTTLMNA | |
| SCHEMBL6608257 | 0.75 | PDE4A (0.33) | MEN1MAPTKMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716834-B2 | ANTICOAGULANTS. | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| EP-1283837-B1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2003-11-27 | — | — | US | disclosed |
| EP-1283837-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087879-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | SERPINC1, F2, TFPI | MEN1 1720/4885MAPT 4711/4885KMT2A 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.